HSD administration possibly protects from dyslipidemia through the downregulation of fatty acid synthase (FAS) and acetyl coenzyme A carboxylase alpha (ACCα), and upregulation of ATP-binding cassette transporters G8 (ABCG8) protein expressions in the liver (Sun et al., 2017). Here, FASN is linked to metabolic syndrome.